NEW YORK (GenomeWeb) – Abbott announced on Wednesday it received CE marking for a new molecular diagnostic test for detecting Mycobacterium tuberculosis.

The new test runs on Abbott's m2000 molecular diagnostic platform, and can be consolidated with the company's HIV-1 detection assay. An MTB inactivation step is included with the MTB test procedure to reduce the risk of airborne infection during the handing of sample material, Abbott said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.